Fujifilm said Tuesday it will invest $200 million in cell therapy manufacturing, earmarking the new funds for an area of drug research it expects to grow considerably in the coming years.
The investments will go to two subsidiaries focused on cell therapy production. One of them, Fujifilm Cellular Dynamics, is a developer of human induced pluripotent stem cells, as well as cells derived from them. The other, Fujifilm Diosynth Biotechnologies, is a contract manufacturer that makes biologics and other therapies.
